Lonza buys five US CDMO sites from Merck KGaA, adding ADC conjugation, viral vector, and LNP manufacturing as CDMO ...
Reversing age-related changes in liver cells reduced circulating amyloid beta and cholesterol in rats, revealing a potential ...
Across SLAS Europe 2026, the focus was on AI and automation, but the tone was notably pragmatic. While AI featured heavily across keynote sessions and vendor demonstrations, the emphasis was less on ...
GLP-1 receptor agonists have become the defining drug class of the decade. Initially developed to treat diabetes, they have exploded into the mainstream as powerful weight-loss agents, reshaping not ...
GLP-1 manufacturing challenges have become the binding constraint on one of the most successful drug classes in history. Demand for semaglutide and tirzepatide outran the industry’s ability to make ...
Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., and SPT Labtech today announced their partnership to deliver validated, automated library preparation workflows that combine Takara ...
Explore how enzymatic DNA synthesis can support longer, more complex constructs for genome editing, mRNA, and synthetic ...
OGT certifies four CytoCell probes under IVDR for CLL and myeloma FISH testing, covering ATM deletion and IGH translocations NGS cannot yet replace ...
Researchers are beginning to uncover differences in brain metabolism and cognitive performance among people with PMOS, but ...
Using bioinformatics and machine learning, scientists probe the depths of fungal genomes to find new compounds for undruggable cancers and infections. Fungi have been at war for millennia. Over the ...
OGT's first dedicated fusion MRD NGS panel targets the roughly one-quarter of AML cases where RNA fusion transcripts, not DNA ...
SINGAPORE—Nanyang Technological University, Singapore (NTU) and the Agency for Science, Technology and Research (A*STAR) have showed that applying “temporal pressure” to the skin of mice can create a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results